Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-) NETs: Data from the CLARINET Study

#1194

Introduction: The CLARINET study showed LAN 120 mg prolonged PFS vs. placebo (PBO) in patients with metastatic EP-NETs.

Aim(s): To explore the relationship between CgA and PFS outcomes.

Materials and methods: Tumour progression (CT scan) and plasma CgA were assessed regularly over 96 wks. PFS outcomes (RECIST 1.0) and tumour response (SD/PD) were evaluated according to change in CgA from baseline to wk 12 and last value (LV) in patients with baseline levels above normal.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,

Keywords: lanreotide, biomarker,